Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Bristol-Myers Squibb Company BMY stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Bristol-Myers Squibb has a trailing twelve months PE ratio of 10.79, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 17.96. If we focus on the stock’s long-term PE trend, the current level puts Bristol-Myers Squibb’ current PE ratio noticeably below its midpoint (which is 21.25) over the past five years.
Further, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 19.97. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Bristol-Myers Squibb has a forward PE ratio (price relative to this year’s earnings) of 11.17, so it is fair to expect an increase in the company’s share price in the near future.
While earnings are certainly important, it is essential to know how much you are paying for the growth of earnings as well. One can easily do that with the PEG ratio (ratio of the P/E to the expected future earnings growth rate). The PEG ratio gives a more complete picture of the valuation of a stock than the P/E ratio.
Bristol-Myers Squibb’s PEG ratio stands at just 1.98, compared with the Zacks Large Cap Pharmaceuticals industry average of 1.82. This suggests an overvalued trading relative to its earnings growth potential right now.
Broad Value Outlook
In aggregate, Bristol-Myers Squibb currently has a Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes BMY a solid choice for value investors.
For example, the P/CF ratio (another great indicator of value) comes in at 10.80, which is slightly better than the industry average of 10.97. Clearly, BMY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Bristol-Myers Squibb might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of C. This gives BMY a VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been disappointing. The current quarter has seen one estimate go higher in the past sixty days and one lower, while the full year estimate has seen three upward and two downward revisions in the same time period.
This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate has fallen 3.7% in the past two months, while the full year estimate has dipped 0.7%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Bristol-Myers Squibb Company Price and Consensus
Bristol-Myers Squibb Company price-consensus-chart | Bristol-Myers Squibb Company Quote
This somewhat bearish trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Bristol-Myers Squibb is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a strong industry rank (top 25% out of more than 250 industries) further supports the growth potential of the stock. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates, analyst sentiment and industry trend to turn favorable in this name first, but once that happens, this stock could be a compelling pick.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research